Search results for " Connective tissue disease"

showing 10 items of 848 documents

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Oncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsLower riskBreast cancerTrastuzumabInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm StagingGynecologyregisterbusiness.industryCarcinoma Ductal BreastAge FactorsAbsolute risk reductionhormone receptorsCancerTriple Negative Breast NeoplasmsMiddle AgedTrastuzumabHER2 receptorsPrognosismedicine.diseaseMetastatic breast cancerConfidence interval3. Good healthpopulation-basedCarcinoma LobularReceptors EstrogenOncologyLinear ModelsFemalemetastatic breast cancernet survivalReceptors Progesteronebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Oestrogen — Androgen Balance in Human Breast and Prostate Cancer

1980

Although we conventionally categorise the hormonal steroids as oestrogens, progestins, corticoids or androgens it is more realistic to consider that the steroids exhibit a continuous spectrum of biological effects.

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classCyproterone acetatemedicine.diseaseAndrogenchemistry.chemical_compoundProstate cancerchemistryInternal medicinemedicineCancer researchskin and connective tissue diseasesbusinessHuman breastBalance (ability)Hormone
researchProduct

Male Breast Cancer: Oncologic Surgery

2020

Many cases of male breast cancer (MBC) have been diagnosed during recent years. The increased incidence of such a mortal disease has pointed out the need for solid and well-defined protocols in order to obtain early diagnosis, effective treatment, as well as a greater long-term survival. Although many similarities with female breast cancer support similar diagnostic and therapeutic paths, recent findings about MBC cell phenotypes and tumor behavior support the need for a more customized ai, t, i, ar. One thing is though sure: nowadays lack of knowledge about MBC needs to stimulate further research and the introduction of more standardized and univocal diagnostic/therapeutic guidelines.

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)Diseasemedicine.diseaseOncologic surgeryBreast cancerInternal medicineMale breast cancermedicineEffective treatmentskin and connective tissue diseasesbusinessQuadrantectomyMastectomy
researchProduct

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

2020

MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26)

Oncologymedicine.medical_specialtydiagnosisDown-RegulationBreast NeoplasmsReal-Time Polymerase Chain ReactionArticleCatalysislcsh:ChemistryInorganic Chemistrybreast cancerBreast cancerInternal medicinemicroRNABiomarkers TumorHumansMedicineDiagnostic biomarkerCirculating MicroRNAPhysical and Theoretical Chemistryskin and connective tissue diseaseslcsh:QH301-705.5Molecular BiologyEarly Detection of CancerplasmaSpectroscopyRetrospective StudiesEarly breast cancerPlasma samplesbusiness.industryOrganic ChemistryGeneral MedicineMiddle Agedmedicine.diseaseComputer Science ApplicationsGene Expression Regulation NeoplasticMicroRNAsROC Curvelcsh:Biology (General)lcsh:QD1-999Potential biomarkersCohortbiomarkerBiomarker (medicine)FemalebusinessInternational Journal of Molecular Sciences
researchProduct

Breast cancer in previously thyroidectomized patients: which thyroid disorders are a risk factor?

2021

The aim of this study was to evaluate whether there are thyroid diseases in which breast cancer will appear later as well as the role of autoimmunity. This was a retrospective observational study. A total of 410 females (thyroid surgery and later breast cancer) and 524 females (thyroid surgery only) were compared with regard to pathological thyroid findings, thyroid hormones, thyroid autoimmunity and type of breast cancer. Thyroid autoimmunity, especially antithyroid peroxidase antibodies, significantly increased the risk of breast cancer (p < 0.01); however, this was not true for other thyroid diseases, including thyroid cancer. No variant of breast cancer was predominant, and only thyroid…

Oncologymedicine.medical_specialtyendocrine systemendocrine system diseases030209 endocrinology & metabolismmedicine.disease_causeAutoimmunityThyroid carcinomaClinical Trial Evaluation03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinethyroid dysfunctionsmedicineRisk factorskin and connective tissue diseasesbusiness.industryThyroidRetrospective cohort studymedicine.diseasethyroid autoantibodiesthyroid carcinomaAnti-thyroid autoantibodiesthyroid disordersmedicine.anatomical_structure030220 oncology & carcinogenesisthyroid autoimmunityThyroid autoimmunitybusinessBiotechnologyFuture Science OA
researchProduct

HER2-positive male breast cancer: an update.

2010

Laura Ottini1, Carlo Capalbo2, Piera Rizzolo1, Valentina Silvestri1, Giuseppe Bronte3, Sergio Rizzo3, Antonio Russo31Department of Experimental Medicine, &amp;ldquo;Sapienza&amp;rdquo; University of Rome, Rome, Italy; 2Medical Oncology, IDI-IRCCS, Rome, Italy; 3Department of Surgical and Oncological Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyAbstract: Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cas…

Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorReviewPharmacologyLapatinibTarget therapyBreast cancerTrastuzumabInternal medicinemedicineEpidermal growth factor receptorskin and connective tissue diseasesneoplasmsNeoadjuvant therapybiologybusiness.industryLapatinibTargets and Therapy [Breast Cancer]Trastuzumabmedicine.diseaseRadiation therapyOncologyMale breast cancerbiology.proteinbusinessmedicine.drug
researchProduct

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

2006

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGenes BRCA2Genes BRCA1Breast NeoplasmsBreast cancerRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAromataseskin and connective tissue diseasesbiologybusiness.industryIncidence (epidemiology)Estrogen AntagonistsHematologymedicine.diseaseClinical trialTamoxifenOncologyChemotherapy AdjuvantRelative riskbiology.proteinHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugAnnals of Oncology
researchProduct

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

2014

// Nicole M. Davis 1 , Melissa Sokolosky 1 , Kristin Stadelman 1 , Stephen L. Abrams 1 , Massimo Libra 2 , Saverio Candido 2 , Ferdinando Nicoletti 2 , Jerry Polesel 3 , Roberta Maestro 4 , Antonino D’Assoro 5 , Lyudmyla Drobot 6 , Dariusz Rakus 7 , Agnieszka Gizak 7 , Piotr Laidler 8 , Joanna Dulinska-Litewka 8 , Joerg Basecke 9 , Sanja Mijatovic 10 , Danijela Maksimovic-Ivanic 10 , Giuseppe Montalto 11,12 , Melchiorre Cervello 12 , Timothy L. Fitzgerald 13 , Zoya N. Demidenko 14 , Alberto M. Martelli 15 , Lucio Cocco 15 , Linda S. Steelman 1 and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA 2 …

Oncologymedicine.medical_specialtytherapy resistanceClass I Phosphatidylinositol 3-Kinasesmedicine.medical_treatmentBreast NeoplasmsReviewBiologyMechanistic Target of Rapamycin Complex 1PI3KMetastasisTargeted therapyPhosphatidylinositol 3-KinasesBreast cancerTARGETED THERAPYInternal medicinemedicinePTENHumansTargeted Therapy Therapy Resistance Mutations PI3K mTOR rapamycinskin and connective tissue diseasesProtein kinase BneoplasmsPI3K/AKT/mTOR pathwayRoswell Park Cancer InstituterapamycinTOR Serine-Threonine KinasesMTORPTEN PhosphohydrolaseCancerTargeted TherapyTherapy Resistancemedicine.diseaseTargeted Therapy; Therapy Resistance; Mutations; PI3K; mTOR; rapamycin3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticOncologyMultiprotein ComplexesCancer researchbiology.proteinFemaleReceptor Epidermal Growth FactormutationRAPAMYCINProto-Oncogene Proteins c-aktMutationsSignal Transduction
researchProduct

Physical forces in blister formation. The role of colloid osmotic pressure and of total osmolality in fluid migration into the rising blister.

1978

The physical forces operative in the fluid migration from the interstitial spaces into the blister cleft have not been directly measured until now. The colloid osmotic pressure and the total osmolality were determined in suction blister fluid after mild suction blister production by a modified “Dermovac” and in blister fluid of patients with dermatitis herpetiformis, bullous allergic contact dermatitis and pemphigus vulgaris and in the sera of healthy persons. The colloid osmotic pressure was measured by means of a recently developed osmometer with a semipermeable membrane between 2 chambers, one of them filled with Ringer solution, the other with the blister fluid or serum sample. The nega…

Oncotic pressureIntracellular Fluidmedicine.medical_specialtyTime FactorsIntracellular FluidDermatologyTranscellular fluidBiochemistryBlisterOsmometerInterstitial fluidOsmotic PressuremedicineOsmotic pressureHumansColloidsskin and connective tissue diseasesMolecular Biologyintegumentary systemChemistryOsmolar ConcentrationCell BiologyFluid transportSurgerySuction blisterBiophysicsThe Journal of investigative dermatology
researchProduct

"Table 4" of "Search for events with large missing transverse momentum, jets, and at least two tau leptons in 7 TeV proton-proton collision data with…

2012

The observed 95% CL limits on the minimal GMSB model parameters Lambda and tan(beta) over the tan(beta) region 0.8 to 6.8.

P P --&gt; JETS .GE.2TAU MMintegumentary systemProton-Proton ScatteringIntegrated Cross Sectiontechnology industry and agricultureExclusive7000.0Jet ProductionCross Sectionskin and connective tissue diseasesSIGhuman activities
researchProduct